n-glycolylneuraminic acid has been researched along with benzyl-alpha-n-acetylgalactosamine in 1 studies
| Studies (n-glycolylneuraminic acid) | Trials (n-glycolylneuraminic acid) | Recent Studies (post-2010) (n-glycolylneuraminic acid) | Studies (benzyl-alpha-n-acetylgalactosamine) | Trials (benzyl-alpha-n-acetylgalactosamine) | Recent Studies (post-2010) (benzyl-alpha-n-acetylgalactosamine) |
|---|---|---|---|---|---|
| 341 | 0 | 142 | 55 | 0 | 9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbat, A; Carrière, V; de Bolos, C; Delannoy, P; Hennebicq-Reig, S; Huet, G; Kim, I; Lesuffleur, T; Real, FX; Ulloa, F; Zweibaum, A | 1 |
1 other study(ies) available for n-glycolylneuraminic acid and benzyl-alpha-n-acetylgalactosamine
| Article | Year |
|---|---|
GalNAc-alpha-O-benzyl inhibits NeuAcalpha2-3 glycosylation and blocks the intracellular transport of apical glycoproteins and mucus in differentiated HT-29 cells.
Topics: Acetylgalactosamine; Benzyl Compounds; Biological Transport; Cell Differentiation; Dose-Response Relationship, Drug; Glycoproteins; Glycosylation; Golgi Apparatus; HT29 Cells; Humans; Microvilli; Mucins; Mucus; N-Acetylneuraminic Acid; Neuraminic Acids; Oligosaccharides | 1998 |